{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:39:02Z","timestamp":1790005142678,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,5,28]],"date-time":"2013-05-28T00:00:00Z","timestamp":1369699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s40262-013-0077-2","type":"journal-article","created":{"date-parts":[[2013,5,27]],"date-time":"2013-05-27T17:51:30Z","timestamp":1369677090000},"page":"805-813","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacokinetics of a Three-Way Drug Interaction Between Danoprevir, Ritonavir and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin"],"prefix":"10.1007","volume":"52","author":[{"given":"Barbara J.","family":"Brennan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian A.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter N.","family":"Morcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercidita T.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiney","family":"Asthappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Goelzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Weigl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick F.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,28]]},"reference":[{"issue":"4 Suppl","key":"77_CR1","first-page":"552A","volume":"56","author":"GT Everson","year":"2012","unstructured":"Everson GT, Cooper C, H\u00e9zode C, et al. High SVR rates with 12 to 24\u00a0weeks of ritonavir-boosted danoprevir plus Peg-IFN\u03b1-2a (40KD)\/RBV in HCV genotype 1 or 4 patients in the DAUPHINE study. Hepatology. 2012;56(4 Suppl):552A.","journal-title":"Hepatology"},{"issue":"5","key":"77_CR2","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jhep.2011.01.046","volume":"55","author":"EJ Gane","year":"2011","unstructured":"Gane EJ, Rouzier R, Stedman C, et al. Antiviral activity, safety, and pharmacokinetics of danoprevir\/ritonavir plus PEG-IFN \u03b1-2a\/RBV in hepatitis C patients. J Hepatol. 2011;55(5):972\u20139.","journal-title":"J Hepatol"},{"issue":"7","key":"77_CR3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2165\/11599700-000000000-00000","volume":"51","author":"MB Reddy","year":"2012","unstructured":"Reddy MB, Chen Y, Haznedar JO, et al. Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug\u2013drug interaction study. Clin Pharmacokinet. 2012;51(7):457\u201365.","journal-title":"Clin Pharmacokinet"},{"issue":"4 Suppl","key":"77_CR4","first-page":"580A","volume":"56","author":"P Goelzer","year":"2012","unstructured":"Goelzer P, Morcos PN, Tran J, et al. Coadministration of ritonavir with the HCV protease inhibitor danoprevir substantially reduces reactive metabolite formation both in vitro and in vivo. Hepatology. 2012;56(4 Suppl):580A.","journal-title":"Hepatology"},{"key":"77_CR5","first-page":"7","volume":"6","author":"T Eley","year":"2012","unstructured":"Eley T, Han Y-H, Huang S-P, et al. In vivo and in vitro assessment of asunaprevir as an inhibitor and substrate of OATP transporters in healthy volunteers. Rev Antivir Ther Infect Dis. 2012;6:7.","journal-title":"Rev Antivir Ther Infect Dis"},{"key":"77_CR6","unstructured":"Park S, Ward W, Beaudet B, et al. In vitro assessment of potential drug\u2013drug interactions between telaprevir and cyclophilin inhibitors in the treatment of chronic hepatitis C. Hepatology. 2011;54(Suppl S1):540A."},{"issue":"6","key":"77_CR7","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1128\/AAC.06283-11","volume":"56","author":"MB Reddy","year":"2012","unstructured":"Reddy MB, Morcos PN, Le Pogam S, et al. Pharmacokinetic\/pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors. Antimicrob Agents Chemother. 2012;56(6):3144\u201356.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"77_CR8","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1128\/AAC.00699-08","volume":"52","author":"SD Seiwert","year":"2008","unstructured":"Seiwert SD, Andrews SW, Jiang Y, et al. Preclinical characteristics of the hepatitis C virus NS3\/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother. 2008;52(12):4432\u201341.","journal-title":"Antimicrob Agents Chemother"},{"key":"77_CR9","unstructured":"Portmann R, Meille C, Poirier A. Danoprevir: in vitro studies on hepatic active uptake in human hepatocytes. Nutley: Hoffmann-La Roche Inc; 2012 (data on file)."},{"key":"77_CR10","unstructured":"Wen B, Huang J. In vivo metabolism of danoprevir. Nutley: Hoffmann-La Roche Inc; 2012 (data on file)."},{"issue":"3","key":"77_CR11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"KM Giacomini","year":"2010","unstructured":"Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215\u201336.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"77_CR12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/bdd.1823","volume":"34","author":"Y Shitara","year":"2013","unstructured":"Shitara Y, Maeda K, Ikejiri K, et al. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos. 2013;34(1):45\u201378.","journal-title":"Biopharm Drug Dispos"},{"key":"77_CR13","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/S0021-9258(18)53221-X","volume":"268","author":"T Saeki","year":"1993","unstructured":"Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077\u201380.","journal-title":"J Biol Chem"},{"issue":"8","key":"77_CR14","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1124\/dmd.106.013615","volume":"35","author":"A Treiber","year":"2007","unstructured":"Treiber A, Schneiter R, H\u00e4usler S, et al. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007;35(8):1400\u20137.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"77_CR15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clpt.2004.03.010","volume":"76","author":"SG Simonson","year":"2004","unstructured":"Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther. 2004;76(2):167\u201377.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"77_CR16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.5414\/CPP40439","volume":"40","author":"JW Park","year":"2002","unstructured":"Park JW, Siekmeier R, Merz M, et al. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int J Clin Pharmacol Ther. 2002;40(10):439\u201350.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"77_CR17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1046\/j.1523-1755.2000.00838.x","volume":"57","author":"I Binet","year":"2000","unstructured":"Binet I, Walln\u00f6fer A, Weber C, et al. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int. 2000;57:224\u201331.","journal-title":"Kidney Int"},{"key":"77_CR18","unstructured":"Neoral\u00ae (cyclosporine capsules, USP). US prescribing information. New Jersey: Novartis Pharmaceuticals Corporation; 2012."},{"key":"77_CR19","first-page":"7","volume":"6","author":"PN Morcos","year":"2012","unstructured":"Morcos PN, Moreira S, Navarro M, et al. Ritonavir-boosted danoprevir (DNVr) may be co-administered without regard to meals or in combination with ranitidine or omeprazole: results of a healthy volunteer pharmacokinetic study. Rev Antiviral Ther Infect Dis. 2012;6:7.","journal-title":"Rev Antiviral Ther Infect Dis"},{"issue":"3","key":"77_CR20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","volume":"158","author":"A Kalliokoski","year":"2009","unstructured":"Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693\u2013705.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"77_CR21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clpt.2004.02.008","volume":"76","author":"R Ding","year":"2004","unstructured":"Ding R, Tayrouz Y, Reidel KD, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther. 2004;76(1):73\u201384.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"77_CR22","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1177\/0091270008323258","volume":"48","author":"S Vaidyanathan","year":"2008","unstructured":"Vaidyanathan S, Camenisch G, Schuetz H, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol. 2008;48(11):1323\u201338.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"77_CR23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejps.2005.11.011","volume":"27","author":"J Keogh","year":"2006","unstructured":"Keogh J, Kunta J. Development, validation and utility of an in vitro technique for assessment of potential clinical drug\u2013drug interactions involving P-glycoprotein. Eur J Pharm Sci. 2006;27(5):543\u201354.","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"77_CR24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/bdd.756","volume":"32","author":"MB Reddy","year":"2011","unstructured":"Reddy MB, Connor A, Brennan BJ, et al. Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible. Biopharm Drug Dispos. 2011;32(5):261\u201375.","journal-title":"Biopharm Drug Dispos"},{"issue":"4","key":"77_CR25","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1034\/j.1600-6143.2001.10415.x","volume":"1","author":"A Asberg","year":"2001","unstructured":"Asberg A, Hartmann A, Fjeldsa E, et al. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant. 2001;1(4):382\u20136.","journal-title":"Am J Transplant"},{"issue":"3","key":"77_CR26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0009-9236(97)90034-5","volume":"62","author":"C Olbricht","year":"1997","unstructured":"Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther. 1997;62(3):311\u201321.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"77_CR27","first-page":"2732","volume":"25","author":"MB Regazzi","year":"1993","unstructured":"Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc. 1993;25(4):2732\u20134.","journal-title":"Transplant Proc"},{"key":"77_CR28","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0006-2952(99)00026-X","volume":"57","author":"J Drewe","year":"1999","unstructured":"Drewe J, Gutmann H, Fricker G, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol. 1999;57:1147\u201352.","journal-title":"Biochem Pharmacol"},{"key":"77_CR29","first-page":"4","volume":"6","author":"PN Morcos","year":"2011","unstructured":"Morcos PN, Chang L, Zhang Y, et al. Danoprevir (DNV) does not change effects of ritonavir (RTV) on the PK of CYP3A substrate midazolam (MDZ) and CYP2C9 substrate warfarin (WAR). Rev Antiviral Ther Infect Dis. 2011;6:4.","journal-title":"Rev Antiviral Ther Infect Dis"},{"issue":"1","key":"77_CR30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0009-9236(95)90067-5","volume":"58","author":"DY Gomez","year":"1995","unstructured":"Gomez DY, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther. 1995;58(1):15\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"77_CR31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199835040-00002","volume":"35","author":"A Hsu","year":"1998","unstructured":"Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998;35(4):275\u201391.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"77_CR32","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/lt.20165","volume":"10","author":"M Vogel","year":"2004","unstructured":"Vogel M, Voigt E, Michaelis HC, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir\/ritonavir in liver-transplanted HIV-infected patients. Liver Transplant. 2004;10(7):939\u201344.","journal-title":"Liver Transplant"},{"issue":"4","key":"77_CR33","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.transproceed.2006.02.013","volume":"38","author":"G Guaraldi","year":"2006","unstructured":"Guaraldi G, Cocchi S, Codeluppi M, et al. Pharmacokinetic interaction between amprenavir\/ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. Transplant Proc. 2006;38(4):1138\u201340.","journal-title":"Transplant Proc"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-013-0077-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-013-0077-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-013-0077-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T23:21:02Z","timestamp":1645572062000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-013-0077-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,28]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["77"],"URL":"https:\/\/doi.org\/10.1007\/s40262-013-0077-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,28]]}}}